Palvella Therapeutics (PVLA) announced that the first patients have been dosed in LOTU, a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of Qtorin 3.9% rapamycin anhydrous gel for the treatment of clinically significant angiokeratomas.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics Adds Independent Dermatology Expert to Board
- Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
- 3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
- De-Risked SELVA Trial Success and Scalable QTORIN Platform Underpin Buy Rating on Palvella
- Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway